Interstitial Photodynamic Therapy (PDT) for the Treatment of Patients with Locally Advanced or Recurrent Head and Neck Cancer - Scorecard - MDSpire

Interstitial Photodynamic Therapy (PDT) for the Treatment of Patients with Locally Advanced or Recurrent Head and Neck Cancer

An NCI/NIH funded Phase 1/2 clinical study (NCT03727061) will evaluate the safety and efficacy of adjuvant Photofrin® mediated I-PDT in patients with locally advanced or recurrent HNC who failed to respond to standard therapy and are not amenable to standard curative treatment.

  • August 5, 2019

Share

Clinical Scorecard: Interstitial Photodynamic Therapy (PDT) for the Treatment of Patients with Locally Advanced or Recurrent Head and Neck Cancer

At a Glance

CategoryDetail
ConditionLocally advanced or recurrent head and neck cancer
Key MechanismsPorfimer sodium (Photofrin®) mediated interstitial photodynamic therapy (I-PDT)
Target PopulationPatients with locally advanced or recurrent head and neck cancer who failed to respond to standard therapy
Care SettingClinical research setting

Key Highlights

  • Promising preliminary experience with I-PDT in head and neck cancer
  • Phase 1/2 clinical study (NCT03727061) evaluating safety and efficacy
  • Targeting patients not amenable to standard curative treatment

Guideline-Based Recommendations

Diagnosis

  • Evaluate patients with locally advanced or recurrent head and neck cancer

Management

  • Consider I-PDT for patients who have failed standard therapy

Monitoring & Follow-up

  • Monitor safety and efficacy in clinical trials

Risks

  • Potential risks associated with I-PDT and patient selection criteria

Patient & Prescribing Data

Patients with locally advanced or recurrent head and neck cancer

Adjuvant use of Photofrin® mediated I-PDT in non-responders to standard therapy

Clinical Best Practices

  • Conduct thorough patient evaluation before I-PDT
  • Engage in clinical trials for innovative treatment options

References

Original Source(s)

Interstitial Photodynamic Therapy (PDT) for the Treatment of Patients with Locally Advanced or Recurrent Head and Neck Cancer

  • August 5, 2019

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer